BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA Breast Cancer

BioMarin Pharmaceutical BMRN announced today that it has dosed the first patient in its Phase 3 program to evaluate BMN 673, its poly ADP-ribose polymerase (PARP) inhibitor, in the treatment of metastatic germline BRCA mutated breast cancer. "It has been very exciting to work with this novel molecule in the preclinical laboratory where we saw it to be best in class.  It is equally exciting to now be involved in the clinical translation of this drug in this genetically defined population of breast cancer patients who may benefit from a treatment option specifically designed for them," said Dennis Slamon, Ph.D., M.D., Chief, Division Hematology/Oncology and Director of Clinical/Translational Research, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at the University of California, Los Angeles.  "Oncology therapy is moving towards a personalized and targeted model with the goal of establishing more effective treatments based on an individual's genetic profile, and BMN 673 could be an important step toward tailoring cancer treatments by tumor type." "Enrolling the first patient is an important milestone in the clinical trial process. We are excited to be part of a trial that not only offers the See full press release